Posted on September 5, 2018 by Sitemaster
A media release issued on Tuesday this week by a usually highly respected medical center in the Los Angeles area is misleadingly entitled, “Hormone therapy can make prostate cancer worse, study finds”. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: androgen-resistant, androgen-sensitive, epigenetic, glutamate, neuroendocrine, transition | 6 Comments »
Posted on October 21, 2016 by Sitemaster
Demonstrating how easy it is to “miss” news that may be important to at least a few members of the prostate cancer community, we have just learned that gallium-68 dotatate ([68Ga]dotatate) PET scanning was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2016 — but not specifically for use in the detection of metastatic or micrometastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer | Tagged: dotatate, gallium-68, NET, neuroendocrine, PSMA | 4 Comments »
Posted on April 7, 2016 by Sitemaster
A research team in Los Angeles has demonstrated that a protein produced by a cancer gene (the MYCN gene) leads to the development of the often deadly, late-stage form of prostate cancer called neuroendocrine prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: aurora A kinase, neuroendocrine | 1 Comment »
Posted on August 5, 2015 by Sitemaster
A newly published analysis by a research team at Southern Illinois University School of Medicine has teased out some additional information about the well-recognized increase in the incidence of neuroendocrine forms of prostate cancer over the past 20 or so years. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: carcinoma, incidence, mortality, neuroendocrine, small cell, survival | Leave a comment »
Posted on May 31, 2015 by Sitemaster
A sophisticated presentation at the annual meeting of the American Society of Clinical Oncology today (on behalf of the West Coast Prostate Cancer “Dream Team”) gave us insights into the the development of neuroendocrine forms of drug-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: histology, intermediate, neuroendocrine, small cell | 1 Comment »
Posted on October 17, 2014 by Sitemaster
A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, Management, neuroendocrine, risk, small cell | 1 Comment »
Posted on July 14, 2010 by Sitemaster
It has been known for years that some types of prostate cancer are more aggressive than others, and that among those more aggressive types are prostate cancer tumors that include so-called “neuroendocrine” cell types. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management | Tagged: cells, metastasis, neuroendocrine, Siah2 | 1 Comment »